A new platform, SolaVAX, aims to help inactivate the SARS-CoV-2 virus — the virus which causes COVID-19 — in patients, and its progress will be a joint project of its creators at Colorado State University and the Biomedical Advanced Research and Development Authority (BARDA).
SolaVAX was developed by CSU’s Infectious Disease Research Center using Riboflavin and ultraviolet light to carry out specific DNA and RNA chemistry on viral, bacterial, or cellular agents. It also has two important traits going for it: for one, it has already demonstrated the ability to inactivate another coronavirus, MERS-CoV; for two, it offers low risk to patients. The low risk is because its photochemistry is specific to nucleic acids and therefore induces no damage or modification to hosts’ immunogens.
The partners are working to demonstrate the process’s utility with SARS-CoV-2, but notably, it has the potential to expand and advance vaccine manufacturing capabilities. BARDA confirmed it could potentially scale up to meet vaccine needs globally.
Researchers will test the platform on stock virus cultures grown in CSU manufacturing facilities. Its creators note that SolaVAX is inexpensive, quick, and offers low toxicity, making it easy to handle, distribute, and manufacture vaccines.
Thanks to work by Raytheon, an advanced new ground system for space-based missile warning recently…
According to the latest Elder Fraud Report from the Federal Bureau of Investigation (FBI), 2023…
Following the deaths of four police officers while executing an arrest warrant in North Carolina…
As a way to crackdown on human trafficking, two U.S. representatives recently introduced the Exposing…
A Department of Defense (DoD) 2040 Task Force (D2T) challenge on talent management innovation drew…
For the first time since its creation in 2004, the Transportation Security Administration’s (TSA) Flight…
This website uses cookies.